GOP gives healthcare reform a thumbs down…but will that be all?

Article

Everyone’s talking about Republicans’ initial effort to thwart healthcare reform through the repeal vote, but will it come to anything?

Everyone’s talking about Republicans’ initial effort to thwart healthcare reform through the repeal vote, but will it come to anything? Here’s what the top news sources have to tell us about what would need to be done for Republicans to truly block Obama’s plan. The “repeal, replace” proposal would take significant efforts on the part of the GOP, so only time will tell…but here’s the word on the street for now.

The Associated Press: GOP's Health Care Repeal: Now For The Hard Part

Politico: Focus Shifts To Second Part Of Republicans' 'Repeal And Replace' Vow  

McClatchy: Hard Part Begins For GOP: Replacing Health Care Law    

Bloomberg: U.S. House Republicans Set To Start Crafting Health-Overhaul Substitute

CQ HealthBeat: Could Talk Of A Middle Ground On Health Care Lead To Action?

Recent Videos
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series
Related Content
Omitting bolus 5-fluouracil in chemotherapy-based treatment for patients with gastrointestinal cancers may reduce adverse effects and healthcare costs.

5-FU Bolus Omission May Reduce Toxicity, Maintain Efficacy in GI Cancers

Russ Conroy
October 14th 2024
Article

Omitting bolus 5-fluouracil in chemotherapy-based treatment for patients with gastrointestinal cancers may reduce adverse effects and healthcare costs.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

The safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.

Fianlimab Combo Shows Activity in Advanced Melanoma Subtypes

Jax DiEugenio
October 14th 2024
Article

The safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.

Novel Allogenic CAR T Therapy Shows Responses in R/R Multiple Myeloma

Courtney Flaherty
October 12th 2024
Article

P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.

Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC

Roman Fabbricatore
October 11th 2024
Article

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.